Antibodies specific for hyperphosphorylated tau and methods of use thereof

Patent metadata

Field	Value
Publication number	US-11739140-B2
Application number	US-202117144355-A
Country	US
Kind code	B2
Filing date	Jan 8, 2021
Priority date	Jul 13, 2015
Publication date	Aug 29, 2023
Grant date	Aug 29, 2023

Abstract

The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

First claim

The invention claimed is:

1. An immunoglobulin molecule comprising:
(a) a Light Chain CDR1 having the amino acid sequence of SEQ ID NO:1;
(b) a Light Chain CDR2 having the amino acid sequence of SEQ ID NO:2;
(c) a Light Chain CDR3 having the amino acid sequence of SEQ ID NO:3;
(d) a Heavy Chain CDR1 having the amino acid sequence of SEQ ID NO:4;
(e) a Heavy Chain CDR2 having the amino acid sequence of SEQ ID NO:5; and
(f) a Heavy Chain CDR3 having the amino acid sequence of SEQ ID NO:6.

2. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is a monoclonal antibody or a bispecific antibody having an Fc domain.

3. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is an epitope-binding fragment of a monoclonal antibody that is selected from the group consisting of: an Fv fragment, an Fv fragment fused to an Fc domain, a Fab fragment, a Fab′ fragment, a F(ab)2 fragment, a single VH variable domain and a single VL variable domain.

4. The immunoglobulin molecule according to claim 1 , wherein said immunoglobulin molecule is a humanized antibody.

5. The immunoglobulin molecule according to claim 1 , comprising the heavy chain of SEQ ID NO:8 and/or the light chain of SEQ ID NO:7.

6. The immunoglobulin molecule according to claim 1 , comprising the heavy chain of SEQ ID NO:8 and/or the light chain of SEQ ID NO:34.

7. A pharmaceutical composition comprising immunoglobulin molecule according to claim 1 , and a pharmaceutical acceptable carrier.

8. A nucleic acid encoding the immunoglobulin molecule according to claim 1 .

9. A method of treating Alzheimer's disease or other tauopathy in a subject in need thereof, said method comprising administering to said subject an effective amount of the immunoglobulin molecule of claim 1 .

10. A method of diagnosing or imaging Alzheimer's disease or other tauopathy in a subject in need thereof, wherein said method comprises administering to said subject an amount of the immunoglobulin molecule of claim 1 sufficient to detect or measure the presence or amount of a hyperphosphorylated variant of human tau in the brain of a said subject.

11. A method of treating Alzheimer's Disease in a subject in need thereof, wherein said method comprises administering to said subject an amount of the immunoglobulin molecule of claim 1 sufficient to reduce or attenuate the accumulation of pathological tau protein in said patient.

12. The immunoglobulin molecule of claim 1 , wherein the immunoglobulin molecule is capable of immunospecifically binding to the phosphorylated residue 396 of human tau (SEQ ID NO:33).

Assignees

• H Lundbeck As

Inventors

• Pedersen Jan Torleif
• Pedersen Lars Østergaard
• Daechsel Justus Claus Alfred
• Asuni Ayodeji Abdur-Rasheed
• Rosenqvist Nina Helen
• Volbracht Christiane
• Helboe Lone
• Elvang Anders Brandt
• Sotty Florence
• Christensen Søren
• Stavenhagen Jeffrey B

Classifications

• C07K16/18 Primary

  against material from animals or humans · CPC title

• A61K39/395 Primary

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61K49/00

  Preparations for testing in vivo · CPC title

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• A61K2039/505

  comprising antibodies · CPC title